Filtered By:
Specialty: Research
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 312 results found since Jan 2013.

Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification.
CONCLUSIONS: Early trends in routine bloodwork and platelet function may serve as novel signatures of patients at risk to experience adverse events. PMID: 31055944 [PubMed - as supplied by publisher]
Source: Biomarkers - May 6, 2019 Category: Research Tags: Biomarkers Source Type: research

Fibrinolytic Enzymes for Thrombolytic Therapy.
Authors: Kumar SS, Sabu A Abstract Cardiovascular diseases are a group of disorders consisting importantly of coronary heart disease, peripheral arterial disease, cerebrovascular disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism. Severe cardiovascular disease conditions lead to acute myocardial infarction and stroke. One of the reasons for this is formation of blood clots inside the vessel. Anticoagulants and antiplatelet drugs are used for managing cardiovascular diseases for a long time. However, they were unable to dissolve an existing thrombus. Fibrinolytic ...
Source: Advances in Experimental Medicine and Biology - September 6, 2019 Category: Research Tags: Adv Exp Med Biol Source Type: research

Synthesis and Evaluation of a Novel Nanoparticle Carrying Urokinase Used in Targeted Thrombolysis.
This article is protected by copyright. All rights reserved. PMID: 31581363 [PubMed - as supplied by publisher]
Source: Biomed Res - October 2, 2019 Category: Research Authors: Zhong Y, Gong WJ, Gao XH, Li YN, Liu K, Hu YG, Qi JS Tags: J Biomed Mater Res A Source Type: research

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Microvascular thrombosis: experimental and clinical implications
A significant amount of clinical and research interest in thrombosis is focused on large vessels (e.g., stroke, myocardial infarction, deep venous thrombosis, etc.); however, thrombosis is often present in the microcirculation in a variety of significant human diseases, such as disseminated intravascular coagulation, thrombotic microangiopathy, sickle cell disease, and others. Further, microvascular thrombosis has recently been demonstrated in patients with COVID-19, and has been proposed to mediate the pathogenesis of organ injury in this disease.
Source: Translational Research - May 22, 2020 Category: Research Authors: Monica A. Bray, Sarah A. Sartain, Jahnavi Gollamudi, Rolando E. Rumbaut Tags: Review Article Source Type: research

Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant.
Conclusion: Our data showed that minor bleeds are common in novel NOAC users, especially when using apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of minor bleeding. PMID: 32573287 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 24, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020.
CONCLUSIONS Telemedicine reduced the delay time of STEMI patients during the COVID-19 pandemic. The difference in short-term adverse clinical outcomes was not statistically significant between patients who used the app and those who did not. PMID: 32938901 [PubMed - in process]
Source: Medical Science Monitor - September 18, 2020 Category: Research Tags: Med Sci Monit Source Type: research

The Impact of Thrombo ‐inflammation on the Cerebral Microcirculation
AbstractThe intertwined processes of thrombosis and inflammation (termed ‘thrombo‐inflammation’) are significant drivers of cerebrovascular diseases and as such they represent prime targets for drug discovery programs focusing on treatment and management of cerebrovascular diseases. Most cerebrovascular events result from chronic systemic microcirculatory dysfuncti on due to underlying conditions e.g. hypertension, diabetes mellitus, coronary artery disease, dyslipidemia and sickle cell disease. Immune cells especially neutrophils play a critical role in the onset as well as maintenance of neuroinflammatory responses...
Source: Microcirculation - February 27, 2021 Category: Research Authors: Junaid Ansari, Felicity N.E. Gavins Tags: REVIEW Source Type: research

Interpretation of myocardial injury subtypes in COVID-19 disease per fourth version of universal definition of myocardial infarction
Conclusions: Objective description of myocardial injury according to the 4th UDMI in current COVID-19 pandemic is crucial in order to discriminate patients with acute myocardial infarction and acute, chronic or incident myocardial injury.PMID:33998352 | DOI:10.1080/1354750X.2021.1921031
Source: Biomarkers - May 17, 2021 Category: Research Authors: Christian Salbach Matthias Mueller-Hennessen Moritz Biener Kiril Stoyanov Michael Preusch Lars Kihm Uta Merle Paul Schnitzler Hugo A Katus Evangelos Giannitsis Source Type: research

Preclinical Assessment of a Novel Conformable Foam-Based Left Atrial Appendage Closure Device
CONCLUSIONS: Preclinical testing demonstrated the conformability of the CLAAS implant and its ability to seal the LAA. Clinical studies are ongoing to characterize the utility of the CLAAS implant in the treatment of patients with atrial fibrillation.PMID:34222469 | PMC:PMC8213491 | DOI:10.1155/2021/4556400
Source: Biomed Res - July 5, 2021 Category: Research Authors: Robert J Sommer Ronald Lamport David Melanson Carol Devellian Andy Levine Christopher M Cain Aaron V Kaplan William A Gray Source Type: research